Insider Buying: Stemline Therapeutics Director Acquires 1,000 Shares of Stock (STML)
Stemline Therapeutics (NASDAQ:STML) Director Kenneth J. Zuerblis acquired 1,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was purchased at an average cost of $11.14 per share, for a total transaction of $11,140.00. Following the completion of the transaction, the director now directly owns 11,963 shares of the company’s stock, valued at approximately $133,268. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Stemline Therapeutics (NASDAQ:STML) traded down 0.64% during mid-day trading on Thursday, hitting $10.85. 63,365 shares of the company’s stock traded hands. Stemline Therapeutics has a 1-year low of $10.509 and a 1-year high of $47.25. The stock has a 50-day moving average of $11.61 and a 200-day moving average of $16.36. The company’s market cap is $140.5 million.
Stemline Therapeutics (NASDAQ:STML) last released its earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.24. On average, analysts predict that Stemline Therapeutics will post $-2.39 earnings per share for the current fiscal year.
Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.